Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319314 | 0.83 | L3MBTL1 (0.52) | ALDH1A1HPGDL3MBTL1NPSR1MAPT | |
| SCHEMBL11255279 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL22381039 | 0.80 | SMN1; SMN2 (0.47) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL11243221 | 0.79 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL29989939 | 0.79 | SMN1; SMN2 (0.45) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL29989947 | 0.79 | KDM4E (0.40) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL4353356 | 0.78 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11253782 | 0.77 | KDM4E (0.45) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL11252571 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 | |
| SCHEMBL22412324 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642451-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024145273-A2 | N-MYRISTOYLTRANSFERASE INHIBITORS AND METHODS OF USE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-116102541-A | Compounds as NMT inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-114174283-B | Compounds as NMT inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20220411431-A1 | Novel compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| CN-114174283-A | Compounds as NMT inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3313833-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF N-MYRISTOYL TRANSFERASE | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2021-01-06 | — | — | EP | disclosed |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| WO-2013083991-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083991-A1 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL INNOVATIONS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-4325962-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIDYRETICS | BYK-GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-04-20 | — | — | US | disclosed |
| US-4146721-A | ANALGESICS, ANTIINFLAMMATORY AGENTS AND ANTIPYRETICS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759804-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | KDM4E 2218/4885ALDH1A1 4471/4885HSD17B10 2260/4885 |
| US-20220411431-A1 | Novel compounds and their use in therapy | NMT1, NMT2, FNTA | KDM4E 2473/4885ALDH1A1 4270/4885HSD17B10 2271/4885 |
| US-11466011-B2 | Compounds and their use as inhibitors of N-myristoyl transferase | NMT1, NMT2, GNMT | KDM4E 2218/4885ALDH1A1 4471/4885HSD17B10 2260/4885 |
| US-20180370974-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | KDM4E 2218/4885ALDH1A1 4471/4885HSD17B10 2260/4885 |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | KDM4E 1816/4885ALDH1A1 1205/4885HSD17B10 3900/4885 |
| US-20200339586-A1 | Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase | NMT1, NMT2, GNMT | KDM4E 2218/4885ALDH1A1 4471/4885HSD17B10 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.